The acquired portfolio consists of 13 ANDAs already approved by the US Food and Drug Administration (FDA) and one pending approval. According to Senores, the total addressable market for these ANDAs in the US is estimated between $421 million and $1.13 billion.
Senores plans to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Also read: Biocon gets FDA nod for cancer drugs lenalidomide and dasatinib
The company stated that the acquired portfolio includes controlled substances and general category drugs, catering to demand across government, retail, and specialty clinics. Senores also sees strong growth potential in other regulated and semi-regulated markets worldwide.
On Tuesday, Dr Reddy’s shares closed nearly flat at ₹11,120.15 on the National Stock Exchange (NSE), while Senores Pharmaceuticals surged 6.03% to ₹562.50 following the announcement.
First Published: Mar 4, 2025 8:34 PM IST
